SMS Pharmaceuticals Limited – Investor Presentation Summary
Key Operational Highlights
- Revenue growth driven by strong volume growth and improved price realization.
- Completed 6 DMF/CEP filings in FY27 to date; on track to meet full-year target of 10 DMF/CEP filings.
- Peptides R&D facility is now fully operational; pilot scale production targeted for Q4FY27.
- Initial CRO revenue from pilot scale production anticipated in Q2FY28.
Key drivers of operational performance: Backward integration projects improving margins, scalable manufacturing enabling operating leverage, and strong foothold in regulated markets.
Segment-wise Performance
- Therapeutic area revenue share: Anti-inflammatory (20%), Anti Retro Viral (ARV) (28%), Anti-diabetic (15%), Anti-migraine (11%), Anti-ulcer (5%), Anti-erectile dysfunction (6%), Anti-epileptic (6%), Anti-anginal (5%), Others (4%).
Explanation of significant changes in segment performance: Not Specified
Financial Highlights
Q2FY27 (Consolidated):
- Revenue: ₹316.08 Crore
- EBITDA: ₹67.65 Crore
- PAT: ₹39.57 Crore (excluding share of profit/(loss) from associate)
- EPS: ₹4.26
- Gross Margin: 35%
- EBITDA Margin: 21%
- PAT Margin: 13% (after share of associate profit/loss)
H1FY27 (Consolidated):
- Revenue: ₹523.05 Crore
- EBITDA: ₹108.60 Crore
- PAT: ₹59.76 Crore (excluding share of profit/(loss) from associate)
- EPS: ₹6.49
- Gross Margin: 36%
- EBITDA Margin: 21%
- PAT Margin: 12% (after share of associate profit/loss)
YoY comparison (Q2FY27 vs Q2FY26):
- Revenue up 30%
- Gross Profit up 41%
- EBITDA up 40%
- PAT up 57%
QoQ comparison (Q2FY27 vs Q1FY27):
- Revenue up 53%
- Gross Profit up 48%
- EBITDA up 65%
- PAT up 96%
Drivers of financial performance: Operating leverage, improved price realization, and benefits of backward integration.
Comparison to market estimates: Not Specified
Key Risks: Not Specified
Geographical Revenue Split
- Revenue from regulated markets: 88%
- Presence in 75+ countries
Domestic vs Export/Regional Revenue: Not Specified
Regional Breakdown: Not Specified
Balance Sheet Snapshot (H1FY27 Consolidated)
- Property, Plant and Equipment: ₹579.47 Crore
- Capital Work-in-Progress: ₹138.26 Crore
- Inventories: ₹377.74 Crore
- Trade Receivables: ₹243.29 Crore
- Cash and Cash Equivalents: ₹36.11 Crore
- Total Equity: ₹842.70 Crore
- Borrowings (Non-Current + Current): ₹349.48 Crore
- Net Debt/Equity: Not Specified
- Reserves: Not Specified
- Current Assets: ₹685.73 Crore
- Current Liabilities: ₹411.18 Crore
Financial Health Insights: Not Specified
Capex & Cash Flow Health
Capex:
- ₹280 crore capital expenditure program on track for completion by FY27.
- H1FY27 Capex: ₹85.88 Crore
- Capex oriented towards capacity expansion for existing APIs, building capacities for new API pipeline, and land acquisition for a greenfield project.
Cash Flow (H1FY27):
- Cash flow from operating activities: ₹105.76 Crore
- Cash flow from investing activities: -₹85.44 Crore
- Cash flow from financing activities: -₹30.08 Crore
- Free Cash Flow: Not Specified
- Operating Cash Flow: ₹105.76 Crore
- Net Debt Movement: Not Specified
Investment Rationale: Focus on capacity expansion, technology upgrades, and delivering returns in the high-teens range.
Strategic & R&D Initiatives
Investments in Innovation:
- Strategic R&D focus with 200+ scientists.
- 130+ DMFs filed till date.
- 35+ process patents.
- JV with Spanish pharma giant Chemo Iberica S.A.
- Product pipeline includes Anti-inflammatory, Anti-diabetic, Anti-depressant (Lab Scale Development & Commercial Validation Completed), and Anti-hypertensive, Antipsychotic, Ulcerative colitis (Lab scale development and validation completed).
Expected impact on growth: Targeting to become the #1 player in the world in Anti-inflammatory APIs; aiming to generate additional revenues through arrangement with Chemo.
Strategic Rationale: Expanding into high-growth markets, reducing operational costs, and improving quality of earnings through backward integration.
Industry Trends & Business Environment
Macro/Industry Trends: Not Specified
Impact on Company: Not Specified
Management Commentary & Growth Outlook
Strategic Outlook: Focused strategy in place to deliver revenue growth with margin expansion.
FY Guidance: FY27 revenue growth and EBITDA margins are now expected to exceed earlier guidance.
Market Share Targets: Targeting to become the #1 player in the world in Anti-inflammatory APIs; aiming for market share wins in key APIs.
Risks and Opportunities: Not Specified